Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Olema PharmaceuticalsOLMA -3.74%28 EV-to-OCF is -3.20 as of Jul. 29, 2026. GuruFocus rates OLMA with a GF Score™ of 28/100. The stock has 3 warning signs investors should review. Among 1,408 Biotechnology companies, Olema Pharmaceuticals ranks better than 50.99% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Olema Pharmaceuticals's Enterprise Value is $476.03 Mil.
Olema Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-148.72 Mil. Therefore, Olema Pharmaceuticals's EV-to-OCF for today is -3.20.
The historical rank and industry rank for Olema Pharmaceuticals's EV-to-OCF or its related term are showing as below:
OLMA'
s EV-to-OCF Range Over the Past 10 Years
Min: -3.46 Med: 0 Max: -3.19
Current: -3.2
During the past 8 years, the highest EV-to-OCF of Olema Pharmaceuticals was -3.19. The lowest was -3.46. And the median was .
OLMA's EV-to-OCF is ranked better than 50.99% of 1408
companies
in the Biotechnology industry
Industry Median: -3.235
vs OLMA: -3.20
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Olema Pharmaceuticals (NAS:OLMA) EV-to-OCF Explanation
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Olema Pharmaceuticals's PE Ratio (TTM) for today is calculated as:
Olema Pharmaceuticals's share price for today is $11.19.
Olema Pharmaceuticals's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.030.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Olema Pharmaceuticals's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Olema Pharmaceuticals EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Olema Pharmaceuticals's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Olema Pharmaceuticals's EV-to-OCF falls into.
Olema Pharmaceuticals's current Enterprise Value is $476.03 Mil.
Olema Pharmaceuticals's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-148.72 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Olema Pharmaceuticals (OLMA) has a EV-to-OCF of -3.20 as of Jul. 29, 2026. According to the industry distribution chart, Olema Pharmaceuticals ranks #690 out of 1408 companies in the Biotechnology industry, placing it in the top 49%.
Is Olema Pharmaceuticals' EV-to-OCF too high?
Olema Pharmaceuticals' current EV-to-OCF is -3.20. Based on the distribution chart, Olema Pharmaceuticals ranks #690 out of 1408 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Olema Pharmaceuticals has a GF Score™ of 28/100, reflecting its overall financial health beyond just this single metric.
How does Olema Pharmaceuticals' EV-to-OCF compare to EYPT and LXRX?
According to the Biotechnology industry distribution chart, Olema Pharmaceuticals ranks #690 out of 1408 companies for EV-to-OCF. This puts Olema Pharmaceuticals in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Olema Pharmaceuticals's current EV-to-OCF is -3.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Olema Pharmaceuticals stock overvalued right now?
Olema Pharmaceuticals (OLMA) has a current EV-to-OCF of -3.20. The current EV-to-OCF is -3.20. Olema Pharmaceuticals' overall GF Score™ is 28/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Olema Pharmaceuticals (OLMA), the current EV-to-OCF is -3.20 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
28GF Score
Get the complete analysis for OLMA
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OLMA has been successfully added to your 
